Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-01-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
海思科医药集团股份有限公司2020年度非公开发行A股股票发行情况报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度非公开发行A股股票发行情况报告书" which translates to "2020 Non-public Issuance of A Shares Stock Issuance Report" by 海思科医药集团股份有限公司. It details the process, approval, subscription, pricing, allocation, and impact of a non-public stock issuance. It includes detailed information about the issuance procedure, regulatory approvals, subscription prices, investor details, and the impact on the company's capital structure and governance. This is a comprehensive report on a capital raising event through a non-public share issuance. The document is lengthy (15,000 characters) and contains substantive financial and procedural data about the issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report, nor a general regulatory filing, nor a proxy or voting result. Therefore, the correct classification is CAP with high confidence.
2023-01-18 Chinese
华泰联合证券有限责任公司关于海思科医药集团股份有限公司2020年度非公开发行A股股票发行过程和认购对象合规性报告
Capital/Financing Update Classification · 95% confidence The document is a detailed compliance report from Huatai United Securities Co., Ltd. regarding the 2020 non-public issuance of A shares by Hisun Pharmaceutical Group Co., Ltd. It includes specifics on the issuance price, number of shares, subscription process, investor suitability checks, regulatory approvals, and fund verification. The document references regulatory approvals from the China Securities Regulatory Commission and details the entire issuance process and compliance with relevant laws and regulations. This is not an announcement or a brief summary but a comprehensive report on the issuance process and compliance. The content aligns with a Capital/Financing Update as it focuses on the company's fundraising activity and capital structure changes through a non-public stock issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-01-18 Chinese
北京市中伦律师事务所关于海思科医药集团股份有限公司非公开发行股票之发行过程及认购对象合规性的法律意见书
Regulatory Filings
2023-01-18 Chinese
海思科医药集团股份有限公司2020年度非公开发行股票验资报告
Regulatory Filings
2023-01-18 Chinese
关于对控股公司增资暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of capital increase and related party transactions involving the company's subsidiaries and holding companies. It details the amounts and parties involved in the capital injections but does not contain financial statements or comprehensive financial data. The document is relatively short (1097 characters) and serves as an update on a financing activity rather than a full financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-01-10 Chinese
关于获得创新药HSK40118片新药申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1080 characters) from a company about receiving an acceptance notice from the National Medical Products Administration for a new drug application. It contains no financial data, no detailed report, and no regulatory form references. It is an announcement of a regulatory event related to drug approval, not a financial report or detailed filing. The document is informational and fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-01-04 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.